|Free Dividend Report|
|Stock Splits Calendar|
|INCY Stock Split History|
|Preferred Stock Newsletter|
|INCY Options Chain|
|Stock Message Boards|
Incyte (INCY) has 2 splits in our Incyte stock split history database. The first split for INCY took place on November 10, 1997. This was a 2 for 1 split, meaning for each share of INCY owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. INCY's second split took place on September 01, 2000. This was a 2 for 1 split, meaning for each share of INCY owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.
When a company such as Incyte splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the Incyte stock split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Incyte shares, starting with a $10,000 purchase of INCY, presented on a split-history-adjusted basis factoring in the complete Incyte stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||18.33%|
|Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. JAKAFI (ruxolitinib) has been approved for the treatment of patients with intermediate or high-risk myelofibrosis, for the treatment of patients with polycythemia vera, and for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Co. has also obtained a license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia. According to our Incyte stock split history records, Incyte has had 2 splits.|
|INCY Split History Table|
|11/10/1997||2 for 1|
|09/01/2000||2 for 1|
|Healthcare Stock Splits|
|INCY is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: INCY shares outstanding history